BioSpace News Archive

Today marks a major milestone for Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), with the initiation of our first-in-human Phase 1 clinical trial for GLR2007, our internally-invented, cyclin-dependent kinase 4/6 (CDK4/6) inhibitor as a potential therapy for advanced solid tumors.

Trice Medical has partnered with Dr. Sherman Canapp and Dr. Debra Canapp at Canapp Sports Medicine LLC, to launch the world’s first veterinary portable tablet combining both a disposable needle arthroscope and high-quality ultrasound into one system.

Advarra IRB receives full accreditation with no findings, underscoring organizational commitment to high research ethics standards

Aveshka is proud to announce that several Federal Regulatory Agencies, including the Federal Deposit Insurance Corporation and the National Credit Union Administration, have issued five separate contract awards to Aveshka to provide comprehensive technical and advisory services on health and safety and operational matters related to the COVID-19 pandemic.

The Launch of the ViziShot 2 25 G EBUS-TBNA Needle Expands Physician Capabilities in Lung Cancer Diagnosis and Staging

On behalf of the CoVIg-19 Plasma Alliance and other plasma companies, Perreault urges people who have recovered from COVID-19 to consider donating plasma. To learn how and where to donate plasma, please visit TheFightIsInUs.org.

The EPA-approved protocol can be used to evaluate the effectiveness of treatments in reducing microbial contamination in agricultural water

iBIO, the Illinois Biotechnology Innovation Organization, announced the launch of Transform Illinois, http://ibio.org, its innovative new program to enhance pandemic preparedness and recovery, erase health equity barriers and continue to nurture the state’s life sciences community.

Albireo Pharma, Inc. announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat presentation at the virtual William Blair Biotech Focus Conference 2020 on Thursday, August 6, at 2 p.m. EDT.

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today announced that Maria Palasis, Ph.D., Lyra’s President and Chief Executive Officer, will participate in a fireside chat at the William Blair Biotech Focus Conference on Thursday, August 6, 2